REC-3964
Phase 2Terminated 0 views this week 0 watching💤 Quiet
Interest: 21/100
21
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Recurrent Clostridioides Difficile Infection
Conditions
Recurrent Clostridioides Difficile Infection
Trial Timeline
Oct 14, 2024 → May 6, 2025
NCT ID
NCT06536465About REC-3964
REC-3964 is a phase 2 stage product being developed by Recursion Pharmaceuticals for Recurrent Clostridioides Difficile Infection. The current trial status is terminated. This product is registered under clinical trial identifier NCT06536465. Target conditions include Recurrent Clostridioides Difficile Infection.
What happened to similar drugs?
4 of 20 similar drugs in Recurrent Clostridioides Difficile Infection were approved
Approved (4) Terminated (0) Active (16)
🔄Nivolumab + Gemcitabine + Cisplatin + Carboplatin + Paclitaxel + PemetrexedOno PharmaceuticalPhase 3
Hype Score Breakdown
Clinical
12
Activity
0
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06536465 | Phase 2 | Terminated |
Competing Products
20 competing products in Recurrent Clostridioides Difficile Infection